
NASDAQ:IDXX
This summary was created by AI, based on 2 opinions in the last 12 months.
IDEXX Laboratories (IDXX) has recently reported strong performance, with top-line growth accelerating to approximately 15%, contrasting with previous quarters that saw growth in the mid-to-high single digits. Following this positive financial news, the company's share price surged by more than 20% in a single day. Experts view IDXX as a high-quality, capital-light compounder in the pet healthcare sector, which supports a favorable investment thesis. However, the stock is currently trading at around 50 times forward P/E, and its future growth is projected at 8%-9%, leading some experts to express caution regarding new investments at these levels. While they remain comfortable holding existing positions, they suggest waiting for better opportunities to expand holdings in IDXX.
IDEXX Laboratories is a American stock, trading under the symbol IDXX (previously IDXX-Q on Stockchase) on the NASDAQ (IDXX). It is usually referred to as NASDAQ:IDXX or IDXX
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on IDXX (previously IDXX-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for IDEXX Laboratories.
IDEXX Laboratories was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for IDEXX Laboratories.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for IDEXX Laboratories.
IDEXX Laboratories is followed by 14 investors on Stockchase and is a trending stock that is worth watching.
On 2026-07-02, IDEXX Laboratories (IDXX) stock closed at a price of $553.56.
IDXX recently reported solid numbers as its topline growth accelerated to around 15% compared to previous quarters of around mid-to-high single digits. The company reacted favourably to the news as its share price jumped more than 20% in a single day. We think IDXX’s investment thesis as a high-quality, capital-light compounder in the pet healthcare industry remains intact. That being said, IDXX is now trading at around 50x Forward P/E, and growth over the next few years is expected to be around 8%-9%. We are comfortable holding the position here, but we don’t think it is too attractive to add at the current levels. We would prefer to be patient and wait for another opportunity to add to the name.
Unlock Premium - Try 5i Free